Insulin use, adipokine profiles and breast cancer prognosis

Wintrob, Zachary A.P.; Hammel, Jeffrey; Khoury, Thaer; Nimako, George K.; Fu, Hsin Wei; Fayazi, Zahra; Gaile, Dan P.; Forrest, Alan; Ceacareanu, Alice C.

doi:10.1016/j.cyto.2016.10.017

Cited by 19 publications

(41 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data in Table 2 includes the observed correlations between pro-inflammatory C–C chemokines stratified by type 2 diabetes mellitus pharmacotherapy and controls, as well as already reported biomarkers’ correlation with each of the studied C–C chemokines is presented in Table 2. The details regarding adiponectin, leptin, C-reactive protein, C-peptide, tumor necrosis factor α, interleukin 1β and its receptor antagonist, interleukin 6, and interleukin 10 determination from plasma, and their association with cancer outcomes and use of injectable insulin has been previously reported [1] or is reviewed under a separate dataset [2].…”

Section: Datamentioning

confidence: 99%

“…Clinical and treatment history were evaluated in relationship with cancer outcomes and pro-inflammatory cytokine profiles. A biomarker correlation analysis was performed between the studied C-C chemokines and between each of them and the cytokine levels already reported elsewhere for this particular patient population [1], [2], [3], [4], [5], [6], [7], [8], [9]. The additional correlations were provided for completeness and usability of this data.Data source locationUnited States, Buffalo, NY - 42° 53׳ 50.3592"N; 78° 52׳ 2.658"WData accessibilityThe data is with this article…”

mentioning

confidence: 99%

See 1 more Smart Citation

Data report on inflammatory C–C chemokines among insulin-using women with diabetes mellitus and breast cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

Injectable insulin use may interfere with pro-inflammatory cytokines’ production and, thus, play a role in the activation of tumor-associated macrophages - a process mainly influenced by inflammatory C–C chemokines. The data presented shows the relationship between pre-existing use of injectable insulin in women diagnosed with breast cancer and type 2 diabetes mellitus, the inflammatory C–C chemokine profiles at the time of breast cancer diagnosis, and subsequent cancer outcomes. A Pearson correlation analysis stratified by insulin use and controls is also provided. We present the observed relationship between the investigated C–C chemokines and between each of these biomarkers and previously reported adipokines levels in this study population [1].

show abstract

Section: Datamentioning

confidence: 99%

mentioning

confidence: 99%

Data report on inflammatory C–C chemokines among insulin-using women with diabetes mellitus and breast cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…As described in the original research article by Wintrob et al [1], all incident breast cancer cases diagnosed at Roswell Park Cancer Institute (01/01/2003-12/31/2009) were considered for inclusion ( n =2194). Medical and pharmacotherapy history were used to determine the baseline presence of diabetes.…”

Section: Experimental Design Materials and Methodsmentioning

confidence: 99%

“…For a specific breakdown of excluded subjects, please see the original research article by Wintrob et al [1].…”

Section: Experimental Design Materials and Methodsmentioning

confidence: 99%

“…Mean overall and disease-free survival were 113.3 and 107.3 months respectively, both with a minimum follow-up of 25.6 months. For additional details concerning data collection, specific definitions regarding censoring and drug use (including the number of insulin users per analyzed group), and a comprehensive demographic report, please see the original article by Wintrob et al [1].…”

Section: Experimental Design Materials and Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

Oral drugs stimulating insulin production may impact growth factor levels. The data presented shows the relationship between pre-existing insulin secretagogues use, growth factor profiles at the time of breast cancer diagnosis and subsequent cancer outcomes in women diagnosed with breast cancer and type 2 diabetes mellitus. A Pearson correlation analysis evaluating the relationship between growth factors stratified by diabetes pharmacotherapy and controls is also provided.

show abstract

Consumption of sugar‐sweetened and artificially sweetened beverages and breast cancer survival

Farvid

Spence

Rosner

et al. 2021

Cancer

View full text Add to dashboard Cite

Background The activation of insulin pathways is hypothesized to promote tumor growth and worsen breast cancer survival. Sugar‐sweetened beverages (SSBs) can lead to a higher risk of insulin resistance and may affect survival. The authors prospectively evaluated the relation of postdiagnostic SSB and artificially sweetened beverage (ASB) consumption with mortality among women with breast cancer. Methods In total, 8863 women with stage I through III breast cancer were identified during follow‐up of the Nurses' Health Study (NHS; 1980‐2010) and Nurses' Health Study II (NHSII; 1991‐2011). Women completed a validated food frequency questionnaire every 4 years after diagnosis and were followed until death or the end of follow‐up (2014 for the NHS and 2015 for the NHSII). Multivariable Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of breast cancer‐specific and all‐cause mortality after adjusting for measures of adiposity and other potential predictors of cancer survival. Results With a median follow‐up of 11.5 years, 2482 deaths were prospectively documented, including 1050 deaths from breast cancer. Compared with women who had no consumption, women who had SSB consumption after diagnosis had higher breast cancer‐specific mortality (>1 to 3 servings per week: HR, 1.31 [95% CI, 1.09‐1.58]; >3 servings per week: HR, 1.35 [95% CI, 1.12‐1.62]; Ptrend = .001) and all‐cause mortality (>1 to 3 servings per week: HR, 1.21 [95% CI, 1.07‐1.37]; >3 servings per week: HR, 1.28 [95% CI, 1.13‐1.45]; Ptrend = .0001). In contrast, ASB consumption was not associated with higher breast cancer‐specific or all‐cause mortality. Furthermore, replacing 1 serving per day of SSB consumption with 1 serving per day of ASB consumption was not associated with a lower risk of mortality. Conclusions Higher postdiagnostic SSB consumption among breast cancer survivors was associated with higher breast cancer‐specific mortality and death from all causes.

show abstract

Insulin use, adipokine profiles and breast cancer prognosis

Cited by 19 publications

References 70 publications

Data report on inflammatory C–C chemokines among insulin-using women with diabetes mellitus and breast cancer

Data report on inflammatory C–C chemokines among insulin-using women with diabetes mellitus and breast cancer

Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer

Consumption of sugar‐sweetened and artificially sweetened beverages and breast cancer survival

Contact Info

Product

Resources

About